📣 Our operator @inmaruca.bsky.social presented #BioBlue at #InnovAzul2026! 🌊
🧬 Launching in 2027, the project will explore Andalusian marine biodiversity using #EMO_BON protocols and @embrcspain.bsky.social's marine and aerial drones.
@embrc.eu #BlueBiotech
🧬 Launching in 2027, the project will explore Andalusian marine biodiversity using #EMO_BON protocols and @embrcspain.bsky.social's marine and aerial drones.
@embrc.eu #BlueBiotech
November 3, 2026 at 1:14 PM
📣 Our operator @inmaruca.bsky.social presented #BioBlue at #InnovAzul2026! 🌊
🧬 Launching in 2027, the project will explore Andalusian marine biodiversity using #EMO_BON protocols and @embrcspain.bsky.social's marine and aerial drones.
@embrc.eu #BlueBiotech
🧬 Launching in 2027, the project will explore Andalusian marine biodiversity using #EMO_BON protocols and @embrcspain.bsky.social's marine and aerial drones.
@embrc.eu #BlueBiotech
Hola chicos, vendo microscopio Euromex BioBlue Bb.4260. Apenas lo he usado, entrega en Madrid y precio negociable. Lo vendo hasta con muestras y con todo el tinglado que trae. Conectable a PC.
October 5, 2026 at 10:35 AM
Hola chicos, vendo microscopio Euromex BioBlue Bb.4260. Apenas lo he usado, entrega en Madrid y precio negociable. Lo vendo hasta con muestras y con todo el tinglado que trae. Conectable a PC.
Roland Pihlakas, Sruthi Kuriakose: BioBlue: Notable runaway-optimiser-like LLM failure modes on biologically and economically aligned AI safety benchmarks for LLMs with simplified observation... https://arxiv.org/abs/2509.02655 https://arxiv.org/pdf/2509.02655 https://arxiv.org/html/2509.02655
September 4, 2025 at 6:30 AM
Roland Pihlakas, Sruthi Kuriakose: BioBlue: Notable runaway-optimiser-like LLM failure modes on biologically and economically aligned AI safety benchmarks for LLMs with simplified observation... https://arxiv.org/abs/2509.02655 https://arxiv.org/pdf/2509.02655 https://arxiv.org/html/2509.02655
quick series on emerging #cancer targets w updates post #ASCO25 from the biopharma/venture capital consultancy experts - sugarconebiotech.com #biotech #bioblue
www.sugarconebiotech.com/insights/goo...
www.sugarconebiotech.com/insights/goo...
Good things come in 3s — SugarCone Biotech
DLL3, B7H3 and Her3 are compelling tumor antigens to target with cancer therapeutics. They have interesting patterns of expression in different cancer indications; thus, diverse therapies for attackin...
www.sugarconebiotech.com
June 20, 2025 at 12:31 PM
quick series on emerging #cancer targets w updates post #ASCO25 from the biopharma/venture capital consultancy experts - sugarconebiotech.com #biotech #bioblue
www.sugarconebiotech.com/insights/goo...
www.sugarconebiotech.com/insights/goo...
March 13, 2025 at 3:53 PM
A bit more #bioblue #biotech #oncology news from aletabiotherapeutics.com - we've invented a remarkable way to boost the functionality of T Cell Engager proteins (TCE) by making tumor cells look more like an immune cell. The "engaged" T cells just LOVE the embrace. www.nature.com/articles/d43...
March 3, 2025 at 1:19 PM
A bit more #bioblue #biotech #oncology news from aletabiotherapeutics.com - we've invented a remarkable way to boost the functionality of T Cell Engager proteins (TCE) by making tumor cells look more like an immune cell. The "engaged" T cells just LOVE the embrace. www.nature.com/articles/d43...
hey #bioblue --- in a time of simply ridiculous copycat drug development we found a few examples of real innovation. Part 1 - novel bispecific therapeutics in oncology. Posted only at sugarconebiotech.com.
www.sugarconebiotech.com/insights/nov...
www.sugarconebiotech.com/insights/nov...
March 2, 2025 at 10:17 PM
hey #bioblue --- in a time of simply ridiculous copycat drug development we found a few examples of real innovation. Part 1 - novel bispecific therapeutics in oncology. Posted only at sugarconebiotech.com.
www.sugarconebiotech.com/insights/nov...
www.sugarconebiotech.com/insights/nov...
February 23, 2025 at 10:11 PM
January 10, 2025 at 11:57 AM
The response of the our immune system to #cancer is complex ... and sometimes devastatingly inept. Can we use advanced immune-system hacking to destroy aggressive, advanced tumors? #bioblue #biotech
I have hope: www.sugarconebiotech.com/insights/a-b...
I have hope: www.sugarconebiotech.com/insights/a-b...
A BRIEF REVIEW OF DRUG DEVELOPMENT TARGETING THE LTβ/LTβR PATHWAY — SugarCone Biotech
Companies mentioned: Biogen, Avalo Therapeutics, Pfizer, Roche, Mestag Therapeutics, Shanghai Junshi Bioscience Attempts to modulate the immune activity of the lymphotoxin beta pathway have been long...
www.sugarconebiotech.com
December 2, 2024 at 1:23 PM
The response of the our immune system to #cancer is complex ... and sometimes devastatingly inept. Can we use advanced immune-system hacking to destroy aggressive, advanced tumors? #bioblue #biotech
I have hope: www.sugarconebiotech.com/insights/a-b...
I have hope: www.sugarconebiotech.com/insights/a-b...
Well here we go... The response of the human immune system to cancerous cells is complex and often devastatingly inept. Can we make ourselves more formidable using advanced immune-system hacking? I bet yes ... #bioblue #biotech #medblue
www.sugarconebiotech.com/insights/a-b...
www.sugarconebiotech.com/insights/a-b...
A BRIEF REVIEW OF DRUG DEVELOPMENT TARGETING THE LTβ/LTβR PATHWAY — SugarCone Biotech
Companies mentioned: Biogen, Avalo Therapeutics, Pfizer, Roche, Mestag Therapeutics, Shanghai Junshi Bioscience Attempts to modulate the immune activity of the lymphotoxin beta pathway have been long...
www.sugarconebiotech.com
December 1, 2024 at 9:20 PM
Well here we go... The response of the human immune system to cancerous cells is complex and often devastatingly inept. Can we make ourselves more formidable using advanced immune-system hacking? I bet yes ... #bioblue #biotech #medblue
www.sugarconebiotech.com/insights/a-b...
www.sugarconebiotech.com/insights/a-b...
In #celltherapy news, Roche to acquire Poseida for programs in blood cancers and autoimmunity/inflammation #bioblue #biotech
www.globenewswire.com/news-release...
www.globenewswire.com/news-release...
Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies
Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across oncology, immunology, and...
www.globenewswire.com
November 26, 2024 at 12:41 PM
In #celltherapy news, Roche to acquire Poseida for programs in blood cancers and autoimmunity/inflammation #bioblue #biotech
www.globenewswire.com/news-release...
www.globenewswire.com/news-release...
just pondering stuff that doesn't work and here comes another chemokine - this one to control Tregs in anti-tumor immunity. As I don't believe Tregs do ANYTHING in anti-tumor immunity, I've gotta believe that PF4 targeting will be a bust
www.science.org/doi/10.1126/... also mousey. #bioblue
www.science.org/doi/10.1126/... also mousey. #bioblue
Platelet factor 4–induced TH1-Treg polarization suppresses antitumor immunity
The tumor microenvironment (TME) contains a number of immune-suppressive cells such as T helper 1–polarized regulatory T cells (TH1-Treg cells). However, little is known about the mechanism behind the...
www.science.org
November 22, 2024 at 6:23 PM
just pondering stuff that doesn't work and here comes another chemokine - this one to control Tregs in anti-tumor immunity. As I don't believe Tregs do ANYTHING in anti-tumor immunity, I've gotta believe that PF4 targeting will be a bust
www.science.org/doi/10.1126/... also mousey. #bioblue
www.science.org/doi/10.1126/... also mousey. #bioblue
ok, neat. NK-based cell therapy and mutated-IL2 proteins that have failed clinically may work when brought together by an NK cell engager protein (also targeting CD20). www.science.org/doi/10.1126/...
Or maybe not, as this is MOUSE WORK and the translation to clinic is FRAUGHT... n.b. #bioblue
Or maybe not, as this is MOUSE WORK and the translation to clinic is FRAUGHT... n.b. #bioblue
A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma
IPH6501, a CD20-targeted NK cell engager armed with non-alpha IL-2, shows preclinical efficacy and tolerability in B-NHL.
www.science.org
November 22, 2024 at 6:18 PM
ok, neat. NK-based cell therapy and mutated-IL2 proteins that have failed clinically may work when brought together by an NK cell engager protein (also targeting CD20). www.science.org/doi/10.1126/...
Or maybe not, as this is MOUSE WORK and the translation to clinic is FRAUGHT... n.b. #bioblue
Or maybe not, as this is MOUSE WORK and the translation to clinic is FRAUGHT... n.b. #bioblue
Cool "near-mucosal" immunity governed by a cool-kids couple (GPR25/CXCL17) revealed in "A lymphocyte chemoaffinity axis for lung, non-intestinal mucosae and CNS"
that's some keen #bioblue #immunity
www.nature.com/articles/s41...
that's some keen #bioblue #immunity
www.nature.com/articles/s41...
A lymphocyte chemoaffinity axis for lung, non-intestinal mucosae and CNS - Nature
GPR25 and its ligand define the core chemoaffinity axis GPR25–CXCL17 of the integrated extraintestinal mucosal immune system, regulating how immune responses disseminate to non-intestinal barrier...
www.nature.com
November 20, 2024 at 10:55 PM
Cool "near-mucosal" immunity governed by a cool-kids couple (GPR25/CXCL17) revealed in "A lymphocyte chemoaffinity axis for lung, non-intestinal mucosae and CNS"
that's some keen #bioblue #immunity
www.nature.com/articles/s41...
that's some keen #bioblue #immunity
www.nature.com/articles/s41...
an #openaccess rvw on the development of therapeutics targeting the TNF/TNFR superfamilies. Everything you can imagine is in here www.nature.com/articles/s41... incl LTBR. NOTE: Pfizer's agonist tetravalent anti-LTBR recently terminated after n=4. I'll bet they hit liver tox! #biotech #bioblue
Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer - Nature Reviews Drug Discovery
Members of the TNF superfamily (TNFSF) of ligands and their receptors have emerged as promising targets in the treatment of autoimmune diseases and cancer, with several biologics gaining FDA approval....
www.nature.com
November 19, 2024 at 1:16 PM
an #openaccess rvw on the development of therapeutics targeting the TNF/TNFR superfamilies. Everything you can imagine is in here www.nature.com/articles/s41... incl LTBR. NOTE: Pfizer's agonist tetravalent anti-LTBR recently terminated after n=4. I'll bet they hit liver tox! #biotech #bioblue
also under #bioblue #biotech - A paper in Cell that is singing the Aleta Biotherapeutics technology anthem pubmed.ncbi.nlm.nih.gov/39504957/ building multi-domain solutions for solid tumors. Of course we also tune in a bit of immune system manipulation. aletabio.com
Aleta Biotherapeutics
aletabio.com
November 19, 2024 at 1:04 PM
also under #bioblue #biotech - A paper in Cell that is singing the Aleta Biotherapeutics technology anthem pubmed.ncbi.nlm.nih.gov/39504957/ building multi-domain solutions for solid tumors. Of course we also tune in a bit of immune system manipulation. aletabio.com